WO2005025494A3 - Vaccine immunotherapy for immune suppressed patients - Google Patents

Vaccine immunotherapy for immune suppressed patients Download PDF

Info

Publication number
WO2005025494A3
WO2005025494A3 PCT/US2004/025518 US2004025518W WO2005025494A3 WO 2005025494 A3 WO2005025494 A3 WO 2005025494A3 US 2004025518 W US2004025518 W US 2004025518W WO 2005025494 A3 WO2005025494 A3 WO 2005025494A3
Authority
WO
WIPO (PCT)
Prior art keywords
ncm
effective amount
indo
dendritic cells
skin test
Prior art date
Application number
PCT/US2004/025518
Other languages
French (fr)
Other versions
WO2005025494A2 (en
Inventor
John W Hadden
Original Assignee
Irx Therapeutics Inc
John W Hadden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT04780361T priority Critical patent/ATE526986T1/en
Application filed by Irx Therapeutics Inc, John W Hadden filed Critical Irx Therapeutics Inc
Priority to EP04780361A priority patent/EP1653912B1/en
Priority to DK04780361.4T priority patent/DK1653912T3/en
Priority to ES04780361T priority patent/ES2374920T3/en
Priority to CA002578375A priority patent/CA2578375A1/en
Priority to US10/567,320 priority patent/US20070031372A1/en
Priority to AU2004271930A priority patent/AU2004271930A1/en
Priority to JP2006522764A priority patent/JP2007501798A/en
Publication of WO2005025494A2 publication Critical patent/WO2005025494A2/en
Publication of WO2005025494A3 publication Critical patent/WO2005025494A3/en
Priority to HK06110602.3A priority patent/HK1092695A1/en
Priority to US11/970,073 priority patent/US20090180982A1/en
Priority to US12/475,957 priority patent/US20100310469A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001141—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2

Abstract

A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using an NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and methods for elicting an immune response to endogenous or exogenous tumor antigens.
PCT/US2004/025518 2000-10-27 2004-08-05 Vaccine immunotherapy for immune suppressed patients WO2005025494A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/567,320 US20070031372A1 (en) 2004-08-05 2004-08-05 Vaccine immunotherapy for immune suppressed patients
EP04780361A EP1653912B1 (en) 2003-08-08 2004-08-05 Vaccine immunotherapy for immune suppressed patients
DK04780361.4T DK1653912T3 (en) 2003-08-08 2004-08-05 Vaccine immunotherapy immunocompromised patients
ES04780361T ES2374920T3 (en) 2003-08-08 2004-08-05 VACCINE IMMUNOTHERAPY FOR IMMUNOSUPPRESSED PATIENTS.
CA002578375A CA2578375A1 (en) 2003-08-08 2004-08-05 Vaccine immunotherapy for immune suppressed patients
AT04780361T ATE526986T1 (en) 2003-08-08 2004-08-05 VACCINE IMMUNOTHERAPY FOR IMMUNE-COMPROMISED PATIENTS
AU2004271930A AU2004271930A1 (en) 2003-08-08 2004-08-05 Vaccine immunotherapy for immune suppressed patients
JP2006522764A JP2007501798A (en) 2003-08-08 2004-08-05 Vaccine immunotherapy for immunosuppressed patients
HK06110602.3A HK1092695A1 (en) 2003-08-08 2006-09-22 Vaccine immunotherapy for immune suppressed patients
US11/970,073 US20090180982A1 (en) 2000-10-27 2008-01-07 Vaccine immunotherapy for immune suppressed patients
US12/475,957 US20100310469A1 (en) 2000-10-27 2010-05-26 Vaccine immunotherapy for immune suppressed patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/637,869 US7182942B2 (en) 2000-10-27 2003-08-08 Vaccine immunotherapy for immune suppressed patients
US10/637,869 2003-08-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/637,869 Continuation US7182942B2 (en) 2000-10-27 2003-08-08 Vaccine immunotherapy for immune suppressed patients

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/970,073 Division US20090180982A1 (en) 2000-10-27 2008-01-07 Vaccine immunotherapy for immune suppressed patients
US12/475,957 Division US20100310469A1 (en) 2000-10-27 2010-05-26 Vaccine immunotherapy for immune suppressed patients

Publications (2)

Publication Number Publication Date
WO2005025494A2 WO2005025494A2 (en) 2005-03-24
WO2005025494A3 true WO2005025494A3 (en) 2005-06-30

Family

ID=34312591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025518 WO2005025494A2 (en) 2000-10-27 2004-08-05 Vaccine immunotherapy for immune suppressed patients

Country Status (11)

Country Link
US (2) US7182942B2 (en)
EP (2) EP1653912B1 (en)
JP (2) JP2007501798A (en)
AT (1) ATE526986T1 (en)
AU (1) AU2004271930A1 (en)
CA (1) CA2578375A1 (en)
DK (1) DK1653912T3 (en)
ES (1) ES2374920T3 (en)
HK (1) HK1092695A1 (en)
PT (1) PT1653912E (en)
WO (1) WO2005025494A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
MXPA03003638A (en) 2000-10-27 2004-01-26 Immuno Rx Inc Vaccine immunotherapy for immune suppressed patients.
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
GB0525535D0 (en) * 2005-12-15 2006-01-25 Cgt Corp Tumour treatment
CN101511372B (en) * 2006-07-07 2011-11-16 蒂尔坦制药有限公司 Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
US9157760B2 (en) * 2007-01-12 2015-10-13 Aol Inc. Community mapping and direction indicating
EP2234642B8 (en) * 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Method of increasing immunological effect
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
EP2328919A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
JP5889797B2 (en) 2009-12-08 2016-03-22 アイアールエックス セラピューティクス， インコーポレイテッド Methods to reverse the immunosuppression of Langerhans cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (en) 1979-05-15 1981-01-15 Max Planck Gesellschaft METHOD FOR PRODUCING THYMOSINE ALPHA 1 AND DERIVATIVES THEREOF
US4470926A (en) 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
DE3100974A1 (en) 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Medicaments having immunoregulating action which contain thymosin alpha 1 fragments, and thymosin alpha 1 fragments
US4612365A (en) 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4390623A (en) 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4464355A (en) 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5100664A (en) 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
ES2236719T3 (en) 1994-11-17 2005-07-16 University Of South Florida METHOD TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF SECONDARY IMMUNODEFICIENCY.
KR970030154A (en) * 1995-11-24 1997-06-26 윤종용 Electron gun for colored cathode ray tube
EP0974357A1 (en) 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
MXPA03003638A (en) 2000-10-27 2004-01-26 Immuno Rx Inc Vaccine immunotherapy for immune suppressed patients.
DE10104969C2 (en) 2001-02-03 2002-11-21 Aeg Infrarot Module Gmbh Cold part of a kyro cooler with improved heat transfer
CA2498591A1 (en) 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency

Also Published As

Publication number Publication date
US7182942B2 (en) 2007-02-27
DK1653912T3 (en) 2012-01-30
US20060120996A1 (en) 2006-06-08
ATE526986T1 (en) 2011-10-15
EP2420249A1 (en) 2012-02-22
HK1092695A1 (en) 2007-02-16
ES2374920T3 (en) 2012-02-23
CA2578375A1 (en) 2005-03-24
JP2012144579A (en) 2012-08-02
EP1653912A4 (en) 2007-09-12
AU2004271930A1 (en) 2005-03-24
JP2007501798A (en) 2007-02-01
US20040071658A1 (en) 2004-04-15
EP1653912A2 (en) 2006-05-10
EP1653912B1 (en) 2011-10-05
WO2005025494A2 (en) 2005-03-24
PT1653912E (en) 2012-01-16

Similar Documents

Publication Publication Date Title
WO2005025494A3 (en) Vaccine immunotherapy for immune suppressed patients
Zhang et al. Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response
JP2010516259A5 (en)
JP2009197032A (en) Immunotherapy to reverse immunosupression
CA2907574C (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
CN108295087A (en) Furin, which strikes to subtract, to be enhanced with GM-CSF（FANG）Cancer vaccine
AR068984A1 (en) PROCESS FOR OBTAINING CELLS PRESENTING ACTIVATED ANTIGENS, USEFUL IN THE THERAPIES AGAINST CANCER AND RELATED ILLNESSES OF THE IMMUNOLOGICAL SYSTEM
KR102195221B1 (en) Pharmaceutical composition for combination of radiotherapy for treating triple negative breast cancer comprising phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 inhibitor
MXPA03003638A (en) Vaccine immunotherapy for immune suppressed patients.
AU2002342151A1 (en) Immunotherapy for reversing immune suppression
US9827288B2 (en) Method for treating a refractory or relapsed lung cancer
Sang et al. Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity
Meng et al. Synergistic effect of methionine encephalin (MENK) combined with pidotimod (PTD) on the maturation of murine dendritic cells (DCs)
KR20220139445A (en) Combinational therapies for treatment of cancer
WO2002053176A3 (en) An autologous anti-cancer vaccine
US8367075B2 (en) Synergistic combination and method thereof
US10952975B2 (en) Compositions and methods for treatment of cancer
EP1815856A2 (en) A cancer vaccine
CN1703504A (en) Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vivo$
US20220235325A1 (en) Stimulation of dendritic cell activity by homotaurine and analogues thereof
Swamy Adoptive In Situ Vaccination with Cyclical Intermittent Stereotactic Body Radiotherapy (SBRT) and Immunotherapy–a Review and Proposed Strategy
ATE356632T1 (en) MELANOMA VACCINE AND ITS PRODUCTION AND USE
US20230233633A1 (en) Method for treating pd-l1 expressing cancer
WO2024057892A1 (en) Anti-tumor immune response enhancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001572

Country of ref document: MX

Ref document number: 2006522764

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004271930

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004780361

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1207/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004271930

Country of ref document: AU

Date of ref document: 20040805

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004271930

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004780361

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007031372

Country of ref document: US

Ref document number: 10567320

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2578375

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 10567320

Country of ref document: US